NYSE:HQL · New York Stock Exchange
+$0.11 today
Vol 0.13M · Avg 0.11M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Management quality matters because capital allocation choices determine how much of Tekla Life Sciences Investors earnings power becomes long-term shareholder value. Use this page to compare HQL returns on capital, executive context, insider transactions, ownership signals, and growth trends against peers, then decide whether leadership appears disciplined, aligned, and capable of compounding through changing market conditions.
Return Metrics
ROE, ROIC & ROA over time
ROE
16.7%
avg 5.5%
ROIC
16.6%
avg 3.8%
ROA
16.6%
avg 5.6%
Analysis
ROE is currently the strongest return metric at 16.7% versus its period average of 5.5%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel R. Omstead | Principal Executive Officer, President and Trustee | — | — | 73 | $197,518.03 | 0.65% |
Peter Branner | Chief Investment Officer | — | — | 62 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$133,754.50
Sells
11
$2.53M
Net Sentiment
$2.40M
Net selling
Most Active
Saba Capital Management, L.P.
11 transactions
1–10 of 12
Analysis
Insiders reported 1 buys worth $133,754.50 and 11 sells worth $2.53M over the last 12 months. That adds up to net selling of $2.40M. Saba Capital Management, L.P. was the most active insider with 11 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -27.4% | N/A — |
| Revenue | N/A | N/A | -14.9% | N/A — |
| Net Income | N/A | N/A | -19.5% | N/A — |
| EBIT | N/A | N/A | N/A | N/A — |
Analysis
Recent growth has been strongest in Revenue at -14.9% over three years.
Competitors
Peer companies in the same sector
Gladstone Investment Corp.
NASDAQ:GAIN
$619.63M
Eagle Point Credit Company Inc.
NYSE:ECC
$510.33M
Gladstone Capital Corporation
NASDAQ:GLAD
$441.47M
Crescent Capital BDC, Inc.
NASDAQ:CCAP
$409.73M
Source Capital, Inc.
NYSE:SOR
$383.40M
Barings Corporate Investors
NYSE:MCI
$356.85M
CION Investment Corporation
NYSE:CION
$318.15M
BlackRock TCP Capital Corp.
NASDAQ:TCPC
$281.91M
PennantPark Investment Corporation
NYSE:PNNT
$225.27M
Who manages HQL?
Tekla Life Sciences Investors (HQL) lists 2 active executives. The top listed executive is Daniel R. Omstead, Principal Executive Officer, President and Trustee.
Are HQL insiders buying or selling?
Recent insider activity shows net buying of $3.96M.
Explore More
Continue the stock analysis
Jump to another research area for this company.